How much did Human Metabolome Technologies achieve in EBIT for the current year?
In the current year, Human Metabolome Technologies has achieved an EBIT of 0 JPY.
In 2024, Human Metabolome Technologies's EBIT was 0 JPY, a 0% increase from the 210.98 M JPY EBIT recorded in the previous year.
YEAR | EBIT (undefined JPY) |
---|---|
2026e | - |
2025e | - |
2024e | - |
2023 | 210.98 |
2022 | 191.15 |
2021 | 39.37 |
2020 | -17.04 |
2019 | -526.18 |
2018 | -140.91 |
2017 | -43.33 |
2016 | -70.36 |
2015 | -100.51 |
2014 | -12.3 |
2013 | -104.8 |
2012 | -106.1 |
2011 | 26.4 |
2010 | -40.5 |
2009 | -195.5 |
Human Metabolome Technologies's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
A yearly comparison of Human Metabolome Technologies's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Human Metabolome Technologies's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Fluctuations in Human Metabolome Technologies’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
In the current year, Human Metabolome Technologies has achieved an EBIT of 0 JPY.
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Human Metabolome Technologies.
The EBIT of Human Metabolome Technologies has increased by 0% decreased compared to the previous year.
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
The EBIT of Human Metabolome Technologies is listed in the income statement.
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
Over the past 12 months, Human Metabolome Technologies paid a dividend of 10 JPY . This corresponds to a dividend yield of about 1.52 %. For the coming 12 months, Human Metabolome Technologies is expected to pay a dividend of 10 JPY.
The current dividend yield of Human Metabolome Technologies is 1.52 %.
Human Metabolome Technologies pays a quarterly dividend. This is distributed in the months of .
Human Metabolome Technologies paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 10 JPY are expected. This corresponds to a dividend yield of 1.52 %.
Human Metabolome Technologies is assigned to the 'Health' sector.
To receive the latest dividend of Human Metabolome Technologies from 9/1/2024 amounting to 15 JPY, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.
The last dividend was paid out on 9/1/2024.
In the year 2023, Human Metabolome Technologies distributed 0 JPY as dividends.
The dividends of Human Metabolome Technologies are distributed in JPY.
Our stock analysis for Human Metabolome Technologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Human Metabolome Technologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.